Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes

By LabMedica International staff writers
Posted on 18 Nov 2026

Immune checkpoint inhibitors have improved melanoma treatment and extended survival over the past 15 years. More...

However, many patients do not respond, and reliable biomarkers for predicting treatment response remain limited. Identifying those most likely to benefit could guide treatment decisions and avoid delays in alternative therapies. New research suggests that protein-based tumor signatures may help predict immunotherapy response and survival in melanoma patients.

Researchers at the University of Pittsburgh developed a molecular atlas of melanoma and a protein-based classification method to predict response to immunotherapy. The research focused on the proteome, the complete set of proteins expressed in a tissue or organism, to better understand how molecular characteristics of melanoma tumors influence treatment outcomes. By linking tumor protein patterns with treatment sensitivity and resistance, the approach aims to identify patients most likely to benefit from immunotherapy before treatment begins.

In a study published in Cancer Discovery, researchers analyzed pretreatment melanoma tumors from 183 patients using a comprehensive multi-omics approach. The analysis examined 13 molecular layers, including the genome, proteome, and metabolome, to investigate the biological mechanisms underlying melanoma progression and treatment response. The team identified chemical modifications to proteins associated with patient survival, along with hundreds of potential molecular targets for further investigation.

A companion study published in Clinical Cancer Research analyzed 208 melanoma tumor samples collected before immunotherapy through an international collaboration involving all National Cancer Institute-funded Melanoma Specialized Programs of Research Excellence programs. Using protein expression patterns, researchers identified three distinct melanoma subtypes: an immune-rich group, a group characterized by increased cell proliferation, and a group exhibiting molecular features associated with tumor growth and metastasis. These classifications revealed biological differences that could help explain variations in immunotherapy response.

The three protein-based subtypes showed distinct associations with treatment outcomes, with the immune-rich group demonstrating the strongest response to immunotherapy. Among patients receiving combination immunotherapy, the subtypes were also associated with differences in disease progression and survival. Building on these findings, researchers developed a classifier that uses protein patterns to assign tumors to one of the three groups. The model was independently validated in two patient cohorts, where it predicted treatment response categories and progression-free survival with a high degree of certainty.

The research involved collaborations among the University of Pittsburgh, UPMC Hillman Cancer Center, Icahn School of Medicine, Fred Hutchinson Cancer Center, University of Michigan, and Pacific Northwest National Laboratory. Together, the studies highlight the potential of comprehensive molecular profiling and protein-based classification to improve immunotherapy response prediction and support more personalized treatment strategies for patients with melanoma.

Further validation is needed, but the findings lay groundwork for more personalized immunotherapy selection based on likely responsiveness and prognosis before treatment starts.

“We currently lack robust biomarkers to predict which patients will derive benefit from combination immunotherapy. A proteomic biomarker could identify tumors most likely to respond, providing the foundation for a clinical assay to guide treatment selection. Once translated into a validated clinical assay, the biomarker could allow pathology laboratories across the country, from Pittsburgh to Palm Beach, to help determine whether a patient is likely to benefit from treatment,” said Diwakar Davar, M.D., associate professor of medicine at Pitt and co-leader of the Cancer Immunology and Immunotherapy Program at UPMC Hillman Cancer Center.

Related Links
University of Pittsburgh
UPMC Hillman Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.